{"protocolSection": {"identificationModule": {"nctId": "NCT04207840", "orgStudyIdInfo": {"id": "API-E004-CL-I"}, "organization": {"fullName": "Amphastar Pharmaceuticals, Inc.", "class": "INDUSTRY"}, "briefTitle": "Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals", "officialTitle": "Study of Drug Exposure in Systemic Circulation of Primatene Mist (0.25mg) by Oral Inhalation, Versus Epinephrine Injection (0.30mg) by Intramuscular Injection and ProAir (0.18mg) by Oral Inhalation in Healthy Individuals: A Randomized, Safety Evaluator-blind, Three-Treatment, Crossover, Fasting Study"}, "statusModule": {"statusVerifiedDate": "2021-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-12-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-12-20", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-12-23", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-12-19", "studyFirstSubmitQcDate": "2019-12-19", "studyFirstPostDateStruct": {"date": "2019-12-23", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-01-25", "resultsFirstSubmitQcDate": "2021-03-04", "resultsFirstPostDateStruct": {"date": "2021-03-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-03-04", "lastUpdatePostDateStruct": {"date": "2021-03-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Amphastar Pharmaceuticals, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To assess the drug exposure profile in systemic circulation of Primatene Mist by inhalation, versus Epinephrine by intramuscular injection, and ProAir HFA by inhalation in healthy adults."}, "conditionsModule": {"conditions": ["Pharmacokinetics", "Epinephrine", "Albuterol", "Asthma", "Anaphylaxis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["INVESTIGATOR"]}}, "enrollmentInfo": {"count": 28, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Primatene Mist, E004", "type": "EXPERIMENTAL", "description": "Participants who dosed with Primatene Mist.", "interventionNames": ["Combination Product: Epinephrine (0.125 mg/inhalation)"]}, {"label": "Epinephrine Injection Auto-Injector (Generic of EpiPen)", "type": "ACTIVE_COMPARATOR", "description": "Participants who were dosed with an Epinephrine Injection Auto-Injector.", "interventionNames": ["Combination Product: Epinephrine Injection Auto-Injector (0.3mg/0.3mL)"]}, {"label": "Albuterol HFA", "type": "ACTIVE_COMPARATOR", "description": "Participants who dosed with Albuterol HFA.", "interventionNames": ["Combination Product: Albuterol Sulfate (0.09 mg/inhalation)"]}], "interventions": [{"type": "COMBINATION_PRODUCT", "name": "Epinephrine (0.125 mg/inhalation)", "description": "Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.", "armGroupLabels": ["Primatene Mist, E004"], "otherNames": ["Primatene Mist"]}, {"type": "COMBINATION_PRODUCT", "name": "Epinephrine Injection Auto-Injector (0.3mg/0.3mL)", "description": "Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.", "armGroupLabels": ["Epinephrine Injection Auto-Injector (Generic of EpiPen)"], "otherNames": ["Generic of EpiPen"]}, {"type": "COMBINATION_PRODUCT", "name": "Albuterol Sulfate (0.09 mg/inhalation)", "description": "Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.", "armGroupLabels": ["Albuterol HFA"], "otherNames": ["Albuterol HFA"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "C[Max], Maximum Plasma Concentration of Albuterol or Epinephrine", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. C\\[max\\] will be obtained directly from the plot of PK curve.", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose."}, {"measure": "AUC(0-tm)_TOT, Area Under the Curve (AUC) of Total (Exogenous and Endogenous, if Available) Active Product Ingredient (API) From Time 0 to Time (tm)", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-tm)_TOT will be calculated with the trapezoid method. Time tm is defined as the time after C\\[max\\] is reached where API concentration is reduced to the levels of the same day baseline.", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose."}, {"measure": "AUC(0-tm)_DE, Area Under the Curve (AUC) of Exogenous Active Product Ingredient (API) From Time 0 to Time (tm)", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-tm)_DE will be calculated with the trapezoid method. Time tm is defined as the time after C\\[max\\] is reached where API concentration is reduced to the levels of the same day baseline.", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose."}, {"measure": "AUC(0-inf), Area Under the Curve (AUC) of Albuterol or Epinephrine From Time 0 to Infinity", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-inf) will be calculated with the extrapolation method.", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose."}], "secondaryOutcomes": [{"measure": "t[Max], Time at Which Maximum Plasma Concentration of Albuterol or Epinephrine is Observed", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. t\\[max\\] will be obtained directly from the plot of PK curve when the maximum concentration is observed.", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose."}, {"measure": "t[1/2], Terminal Elimination Half-life of Albuterol or Epinephrine", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine.", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Agree to participate; understand and sign informed consent;\n* Male and female adults, aged 18 to 50 years, inclusive at Screening;\n* Generally healthy and medically stable, with no clinically significant abnormalities based on physical examination and laboratory tests as determined by the Investigators;\n* Have good venous access;\n* Have normal resting blood pressure and normal heart rate (HR) without history of syncope; a subject with out of range blood pressure may be enrolled in the study at the discretion of the Principal Investigator;\n* Have a body mass index (BMI) of 18.0 - 30.0 kg/m\\^2;\n* Female candidates must be \\>1 year post-menopausal or practicing a clinically acceptable form of birth control and confirmed by negative urine or serum pregnancy test at Screening;\n* Negative HIV-Ab, HBs-Ag and HCV-Ab;\n* Negative alcohol test (urine or breathalyzer);\n* Negative drug screening results;\n* Currently non-smoker; have not used any tobacco products for at least three (3) months prior to Screening; and\n* Demonstrate proficiency in the use of MDI and a consistent inhalation time \\>2.0 seconds after training, for at least three (3) times, with a maximum of 5 attempts.\n\nExclusion Criteria:\n\n* Concurrent clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, or malignant diseases.\n* Known intolerance or hypersensitivity to any component of the study drugs (i.e., Epinephrine, Albuterol Sulfate or any sympathomimetic drugs, HFA-134a, thymol, ethanol, ascorbic acid, nitric acid, and hydrochloric acid).\n* Upper or lower respiratory tract infection, or other systemic infection within 6 weeks prior to Screening;\n* Clinically significant abnormalities in the screening/baseline ECG; prolonged corrected QT interval (QTcF) on ECG: men \\>450ms, women: \\>470ms; single or multiple premature ventricular contractions (PVC);\n* Abnormal thyroid function test (if TSH is out of range, refer to T3/T4 for thyroid function assessment);\n* Subject has been on other investigational drug/device studies within 30 days of Screening Visit or planned participation in another investigational drug trial at any time during this trial;\n* Women who are pregnant or lactating or planning a pregnancy during the study period;\n* Subject has donated or lost \\> 500 mL of blood within 3 months of Screening;\n* Evidence of alcohol or drug abuse or dependency within 6 months prior to screening; or\n* Use of any of the prohibited drugs without appropriate washout.", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Amphastar Study Site 0035", "city": "Cypress", "state": "California", "zip": "90630", "country": "United States", "geoPoint": {"lat": 33.81696, "lon": -118.03729}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED", "description": "Access to patient level data and supporting clinical documents may be requested by qualified researchers. Requests will be reviewed on the basis of scientific merit. Patient data will be de-identified to protect the privacy of trial patients in line with applicable laws and regulations."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants were randomized to receive all 3 treatments over 3 treatment periods in a crossover design.", "groups": [{"id": "FG000", "title": "A-B-C", "description": "Subjects received one of the three treatments during each study visit. Visit 1: Treatment A: Two (2) inhalations of Primatene Mist (0.125 mg of epinephrine per inhalation), for a total dosage of 0.25 mg; Visit 2: Treatment B: Intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL), for a total dosage of 0.30 mg; Visit 3: Treatment C: Two (2) inhalations of Albuterol HFA (0.09 mg of albuterol sulfate per inhalation), for a total dosage of 0.18 mg."}, {"id": "FG001", "title": "B-C-A", "description": "Subjects received one of the three treatments during each study visit. Visit 1: Treatment B: Intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL), for a total dosage of 0.30 mg; Visit 2: Treatment C: Two (2) inhalations of Albuterol HFA (0.09 mg of albuterol sulfate per inhalation), for a total dosage of 0.18 mg; Visit 3: Treatment A: Two (2) inhalations of Primatene Mist (0.125 mg of epinephrine per inhalation), for a total dosage of 0.25 mg."}, {"id": "FG002", "title": "C-A-B", "description": "Subjects received one of the three treatments during each study visit. Visit 1: Treatment C: Two (2) inhalations of Albuterol HFA (0.09 mg of albuterol sulfate per inhalation), for a total dosage of 0.18 mg; Visit 2: Treatment A: Two (2) inhalations of Primatene Mist (0.125 mg of epinephrine per inhalation), for a total dosage of 0.25 mg; Visit 3: Treatment B: Intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL), for a total dosage of 0.30 mg."}], "periods": [{"title": "Treatment Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Washout Period 1 (2-7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}, {"title": "Treatment Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Washout Period 2 (2-7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}, {"title": "Treatment Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Study Participants", "description": "All participants who have been randomized."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37.1", "spread": "7.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "14"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "14"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}]}]}, {"title": "Black or African-American", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "C[Max], Maximum Plasma Concentration of Albuterol or Epinephrine", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. C\\[max\\] will be obtained directly from the plot of PK curve.", "populationDescription": "Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Primatene Mist, E004", "description": "Participants who dosed with Primatene Mist.\n\nEpinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg."}, {"id": "OG001", "title": "Epinephrine Injection Auto-Injector (Generic of EpiPen)", "description": "Participants who were dosed with an Epinephrine Injection Auto-Injector.\n\nEpinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh."}, {"id": "OG002", "title": "Albuterol HFA", "description": "Participants who dosed with Albuterol HFA.\n\nAlbuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "240.8", "spread": "2.4"}, {"groupId": "OG001", "value": "704.8", "spread": "1.8"}, {"groupId": "OG002", "value": "599.8", "spread": "1.7"}]}]}]}, {"type": "PRIMARY", "title": "AUC(0-tm)_TOT, Area Under the Curve (AUC) of Total (Exogenous and Endogenous, if Available) Active Product Ingredient (API) From Time 0 to Time (tm)", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-tm)_TOT will be calculated with the trapezoid method. Time tm is defined as the time after C\\[max\\] is reached where API concentration is reduced to the levels of the same day baseline.", "populationDescription": "Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL x hr", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Primatene Mist, E004", "description": "Participants who dosed with Primatene Mist.\n\nEpinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg."}, {"id": "OG001", "title": "Epinephrine Injection Auto-Injector (Generic of EpiPen)", "description": "Participants who were dosed with an Epinephrine Injection Auto-Injector.\n\nEpinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh."}, {"id": "OG002", "title": "Albuterol HFA", "description": "Participants who dosed with Albuterol HFA.\n\nAlbuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.8", "spread": "3.1"}, {"groupId": "OG001", "value": "509.9", "spread": "1.5"}, {"groupId": "OG002", "value": "3332.3", "spread": "1.3"}]}]}]}, {"type": "PRIMARY", "title": "AUC(0-tm)_DE, Area Under the Curve (AUC) of Exogenous Active Product Ingredient (API) From Time 0 to Time (tm)", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-tm)_DE will be calculated with the trapezoid method. Time tm is defined as the time after C\\[max\\] is reached where API concentration is reduced to the levels of the same day baseline.", "populationDescription": "Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL x hr", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Primatene Mist, E004", "description": "Participants who dosed with Primatene Mist.\n\nEpinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg."}, {"id": "OG001", "title": "Epinephrine Injection Auto-Injector (Generic of EpiPen)", "description": "Participants who were dosed with an Epinephrine Injection Auto-Injector.\n\nEpinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh."}, {"id": "OG002", "title": "Albuterol HFA", "description": "Participants who dosed with Albuterol HFA.\n\nAlbuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.4", "spread": "3.6"}, {"groupId": "OG001", "value": "396.3", "spread": "1.6"}, {"groupId": "OG002", "value": "3332.3", "spread": "1.3"}]}]}]}, {"type": "PRIMARY", "title": "AUC(0-inf), Area Under the Curve (AUC) of Albuterol or Epinephrine From Time 0 to Infinity", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. AUC(0-inf) will be calculated with the extrapolation method.", "populationDescription": "Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL x hr", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Primatene Mist, E004", "description": "Participants who dosed with Primatene Mist.\n\nEpinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg."}, {"id": "OG001", "title": "Epinephrine Injection Auto-Injector (Generic of EpiPen)", "description": "Participants who were dosed with an Epinephrine Injection Auto-Injector.\n\nEpinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh."}, {"id": "OG002", "title": "Albuterol HFA", "description": "Participants who dosed with Albuterol HFA.\n\nAlbuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.4", "spread": "3.6"}, {"groupId": "OG001", "value": "411.4", "spread": "1.7"}, {"groupId": "OG002", "value": "3650.4", "spread": "1.3"}]}]}]}, {"type": "SECONDARY", "title": "t[Max], Time at Which Maximum Plasma Concentration of Albuterol or Epinephrine is Observed", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine. t\\[max\\] will be obtained directly from the plot of PK curve when the maximum concentration is observed.", "populationDescription": "Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "min", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Primatene Mist, E004", "description": "Participants who dosed with Primatene Mist.\n\nEpinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg."}, {"id": "OG001", "title": "Epinephrine Injection Auto-Injector (Generic of EpiPen)", "description": "Participants who were dosed with an Epinephrine Injection Auto-Injector.\n\nEpinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh."}, {"id": "OG002", "title": "Albuterol HFA", "description": "Participants who dosed with Albuterol HFA.\n\nAlbuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.6", "spread": "3.0"}, {"groupId": "OG001", "value": "8.3", "spread": "2.7"}, {"groupId": "OG002", "value": "21.8", "spread": "3.1"}]}]}]}, {"type": "SECONDARY", "title": "t[1/2], Terminal Elimination Half-life of Albuterol or Epinephrine", "description": "Pharmacokinetic (PK) blood samples will be collected starting 30 minutes before dose and until 24 hours after dose. Plasma will be isolated for analyzing the concentrations of Albuterol and Epinephrine.", "populationDescription": "Per Protocol Population, defined as all subjects who have received all study medications and are evaluable for all treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "min", "timeFrame": "Samples were drawn at 30 minutes pre-dose and at 1, 2, 3, 5, 7, 9, 12, 15, 18, 21, 25, 30, 40, 50, 60, 70, 80, 90, 120 minutes, 4, 6, 8, 12, 18, and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Primatene Mist, E004", "description": "Participants who dosed with Primatene Mist.\n\nEpinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg."}, {"id": "OG001", "title": "Epinephrine Injection Auto-Injector (Generic of EpiPen)", "description": "Participants who were dosed with an Epinephrine Injection Auto-Injector.\n\nEpinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh."}, {"id": "OG002", "title": "Albuterol HFA", "description": "Participants who dosed with Albuterol HFA.\n\nAlbuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.1", "spread": "5.2"}, {"groupId": "OG001", "value": "138.8", "spread": "4.0"}, {"groupId": "OG002", "value": "420.7", "spread": "1.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "From signing of consent until follow-up (approximately 4 weeks)", "eventGroups": [{"id": "EG000", "title": "Primatene Mist, E004", "description": "Participants who dosed with Primatene Mist.\n\nEpinephrine (0.125 mg/inhalation): Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.", "deathsNumAffected": 0, "deathsNumAtRisk": 27, "seriousNumAffected": 0, "seriousNumAtRisk": 27, "otherNumAffected": 3, "otherNumAtRisk": 27}, {"id": "EG001", "title": "Epinephrine Injection Auto-Injector (Generic of EpiPen)", "description": "Participants who were dosed with an Epinephrine Injection Auto-Injector.\n\nEpinephrine Injection Auto-Injector (0.3mg/0.3mL): Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.", "deathsNumAffected": 0, "deathsNumAtRisk": 26, "seriousNumAffected": 0, "seriousNumAtRisk": 26, "otherNumAffected": 1, "otherNumAtRisk": 26}, {"id": "EG002", "title": "Albuterol HFA", "description": "Participants who dosed with Albuterol HFA.\n\nAlbuterol Sulfate (0.09 mg/inhalation): Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.", "deathsNumAffected": 0, "deathsNumAtRisk": 28, "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 2, "otherNumAtRisk": 28}], "otherEvents": [{"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Injection Site Pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Nasopharyngitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Amphastar Pharmaceuticals, Inc.", "organization": "Amphastar Pharmaceuticals, Inc.", "email": "info@amphastar.com", "phone": "(909) 980-9484"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-11-08", "uploadDate": "2021-01-25T14:25", "filename": "Prot_000.pdf", "size": 1336549}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-10-13", "uploadDate": "2021-01-25T14:26", "filename": "SAP_001.pdf", "size": 1355238}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-02-09", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000053120", "term": "Respiratory Aspiration"}, {"id": "D000000707", "term": "Anaphylaxis"}], "ancestors": [{"id": "D000012120", "term": "Respiration Disorders"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "asFound": "Inhalation", "relevance": "HIGH"}, {"id": "M4556", "name": "Asthma", "relevance": "LOW"}, {"id": "M4038", "name": "Anaphylaxis", "asFound": "Anaphylaxis", "relevance": "HIGH"}, {"id": "M14957", "name": "Respiration Disorders", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000004837", "term": "Epinephrine"}, {"id": "D000064705", "term": "Racepinephrine"}, {"id": "D000000420", "term": "Albuterol"}, {"id": "C000018285", "term": "Epinephryl borate"}], "ancestors": [{"id": "D000000316", "term": "Adrenergic alpha-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000009184", "term": "Mydriatics"}, {"id": "D000013566", "term": "Sympathomimetics"}, {"id": "D000014662", "term": "Vasoconstrictor Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}], "browseLeaves": [{"id": "M7992", "name": "Epinephrine", "asFound": "Intra-", "relevance": "HIGH"}, {"id": "M30371", "name": "Racepinephrine", "asFound": "Intra-", "relevance": "HIGH"}, {"id": "M211043", "name": "Epinephryl borate", "asFound": "Intra-", "relevance": "HIGH"}, {"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M19560", "name": "Procaterol", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3668", "name": "Adrenergic alpha-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M12139", "name": "Mydriatics", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}, {"id": "M17409", "name": "Vasoconstrictor Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}]}}, "hasResults": true}